• chaogomu@kbin.social
    link
    fedilink
    arrow-up
    8
    ·
    1 year ago

    This is the third (actually second) new Alzheimer’s drug of the last 3 or so years.

    Aducanumab - The first one, and possibly the most useless of them. The newest studies say reduces degradation by 2%
    Lecanemab - The second, reduces degradation by 27%
    Donanemab - This newest drug, reduces degradation by 35%

    All three are based on the same mechanisms, so I don’t know if you could double-dip on medications.

    • TH1NKTHRICE@lemmy.ca
      link
      fedilink
      arrow-up
      1
      ·
      1 year ago

      Even if you could, would you want to double dip into your grandchildren’s savings and increase risk of ARIA (major risk of brain bleeds) all for a guarantee you’re going to die early and with dementia anyway?

  • VenoraTheBarbarian@lemmy.world
    link
    fedilink
    arrow-up
    6
    ·
    1 year ago

    As someone with Alzheimer’s in their family history this is very relieving news. Obviously I might not get it, but it’s nice to know that by the time I do (if I do) it won’t be like it was for my granddad. Hell I’m not even 40 yet, maybe it’ll basically have a cure, or a preventative.

    Maybe this disease will no longer be devastating families soon.